Orlistat under review after links to liver problems

By Admin
Weight loss drug orlistat has come under review by the European Medicines Agency (EMA) after four recent cases of serious liver toxicity were linked to...

Weight loss drug orlistat has come under review by the European Medicines Agency (EMA) after four recent cases of serious liver toxicity were linked to the drug, including one fatal case.

Medicines containing the drug, which has been available since 1998, may have their licenses changed or revoked following the review.

Orlistat was the most commonly prescribed weight loss drug in England in 2009. Since then, other weight loss drugs have been suspended from sale, meaning orlistat has become even more widely prescribed. An estimated 38 million people worldwide have used the drug.

To read the latest edition of Healthcare Global, click here

Orlistat is found in the prescription-only Xenical, as well as over-the-counter medicine, Alli.

In a statement about the review, the EMA commented: “The Committee is now reviewing all relevant data on the risk of hepatotoxicity of orlistat-containing medicines and will issue an opinion on whether or not the marketing authorisations for these medicines should be revoked, suspended or changed.”

Links between orlistat and liver damage have been made in the past, but reports have sometimes been inconclusive. The EMA noted that the number of suspected cases is small compared to the number of people that have used the drug.

Share

Featured Articles

London, Paris & Cambridge 'Healthcare Finance Capitals'

Pitchbook report shows London, Paris and UK's Cambridge dominated investment in healthcare in Q1 2024, with Israel also bouyant

Philips Future Health Index Report: AI to Cut Waiting Times

Healthcare technology leader Philips says virtual care and AI is turning in an effort to cope with demand in its Future Health Index Report 2024

HCLTech and Olympus Advance AI into the Healthcare Industry

Giants HCLTech and Olympus Corporation, have developed their partnership to utilise technology and AI to transform the healthcare industry.

Cancer Vaccines Breakthrough a Glimpse of Healthcare Future

Medical Devices & Pharma

Change Healthcare Cyberattack Fallout Continues

Health Insurance & Finance

McKinsey: National E-health Initiatives on the Rise

Technology & AI